Answers are grounded in this paper and cite their sources.
Round 48 (IRE-48) of the Encevra Research program. Separates condition level cure discharge from record supersession, requires an independent reviewer to extract and provisionally decide from the packet before seeing any brief, and adds a dual domain track of authored clinical protocol amendment packets outside contracts and SEC exhibits, alongside 24 new public filing exhibits. Web version: https://research.encevra.com/round-48
No takes yet. Share an insight, caveat, or question.
Ben Wilkins (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: